The nation of Finland just announced on Thursday that they will be stopping the distribution of Moderna COVID-19 vaccines to younger men, stating that the small risk of heart inflammation exceeds the risk from getting the coronavirus for that particular demographic.
A recent study, which uncovered that men under 30 had a “slightly higher risk than others of developing myocarditis” after receiving the Moderna vaccine, due to be published sometime within the next few weeks.
Mika Salminen, the Finnish health institute’s director, stated that Finland will give these younger men the Pfizer vaccine in the meantime.
Hey, not to burst anyone’s bubble, but that vaccine has been found to cause serious side effects too. Just a little something else to look into.
Moderna said the incidents “are typically mild cases and individuals tend to recover within a short time following standard treatment and rest.”
“The risk of myocarditis is substantially increased for those who contract COVID-19, and vaccination is the best way to protect against this,” the company went on to say.
On Wednesday, Swedish and Danish health officials announced they would pause the use of the Moderna vaccine for all young adults and children, citing the same unpublished study as Finland, the report added.
Myocarditis is the inflammation of the heart muscle, with symptoms including chest pain, shortness of breath, and feelings of having an abnormal heartbeat. The inflammation typically occurs a few days after the second COVID-19 vaccine injection. Despite this possibility, experts at the Centers for Disease Control and Prevention say the benefits of getting vaccinated against COVID-19 outweigh the risks.
Finland has reported 666 new cases of the coronavirus in the last 24 hours. That’s not an ominous number or anything, right? Over 4.1 million individuals have received at least one dose of the vaccine in the country, with 3,520,691 citizens being fully vaccinated as of Monday of this week, according to the World Health Organization.